Precision Medicine News and Research

RSS

Merck Millipore announces joint development agreement with Sysmex Corporation

Merck Millipore, the Life Science division of Merck, today announced a clinical research, licensing and joint development agreement with Sysmex Corporation of Japan.

From Sysmex America, Inc. 18 Mar 2014

Researchers create statistical model to predict whether heart scans are useful in prescribing statins

As long as inexpensive statins, which lower cholesterol, are readily available and patients don't mind taking them, it doesn't make sense to do a heart scan to measure how much plaque has built up in a patient's coronary arteries before prescribing the pills, according to a new study by researchers at UC San Francisco.

17 Mar 2014

Parasites in human are most likely to interact via food source

Over 1,400 species of parasites - viruses, bacteria, fungi, intestinal worms and protozoa - are able to infect humans. In most cases, the right medicine against a parasite cures the patient.

12 Mar 2014

Three innovative tools to detect, test and initiate personalized drug treatment for seizures

A team of researchers from the National Institutes of Health, Emory University and Cedars-Sinai - specialists in identifying and treating very rare diseases - used three innovative tools to detect a previously unknown gene mutation, test potential therapies in the lab, and initiate personalized drug treatment for a boy with a lifelong history of uncontrollable seizures that caused significant impact on his cognitive and social development.

12 Mar 2014

Innovative study uses pharmacogenomic test to treat patients with psychotic disorders

ValueOptions, Inc. a health improvement company specializing in mental and emotional well-being and recovery, and Genomind, a personalized medicine company, today announced an innovative study that uses pharmacogenomic testing to treat patients diagnosed with psychotic disorders, including schizophrenia and bipolar disorder.

11 Mar 2014

Exosome Diagnostics closes Series B financing round with the raising of $27 million

Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas.

11 Mar 2014

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

BerGenBio AS, an oncology biopharmaceutical company, is pleased to announce the award of a NOK 13 million grant from the Research Council of Norway's User-driven Research based Innovation programme (BIA) to help fund research into novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key driver of metastasis (cancer spread) and a mechanism of drug-resistance.

10 Mar 2014

Boston Heart Diagnostics announces commercial launch of FDA-cleared MPO test

Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.

6 Mar 2014

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 DOTATATE.

4 Mar 2014

Advanced Accelerator Applications agrees to acquire 100% shares of Imaging Equipment

Advanced Accelerator Applications, a fast growing international specialist in Molecular Nuclear Medicine (MNM), announced today that it has entered into an agreement to acquire 100% of the shares of Imaging Equipment Ltd, a privately-held UK distributor of nuclear medicine products and technologies, in newly issued AAA shares.

4 Mar 2014

Oxford Gene Technology announces acquisition of Cytocell

Oxford Gene Technology, a provider of innovative genetics research solutions, today announced the acquisition of Cambridge-based Cytocell Limited, a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer.

From Oxford Gene Technology 4 Mar 2014

New tool may hold key to personalized medicine applications in the future

ather than your average bowl of Lucky Charms, these are three-dimensional cell cultures generated by an exciting new digital microfluidics platform, the results of which have been published in Nature Communications this week by researchers at the University of Toronto.

4 Mar 2014

New research uncovers abnormal molecular signaling pathways for kidney failure

Prevention and reversal of chronic kidney disease is an urgent public health need. The disease affects 1 in 10 Americans, is debilitating and deadly, and existing drugs, at best, offer only mild delay in progression to end-stage kidney failure.

4 Mar 2014

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

The incidence of autism spectrum disorders has increased sharply since it was first described 60 years ago. Today, ASD affects more than 1% of all children in the U.S. and about half of them develop a life-long disability.

3 Mar 2014

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

John F. DiPersio, M.D., Ph.D., will be recognized with the 19th Annual American Association for Cancer Research-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.

3 Mar 2014

Study highlights the importance of personalized medicine for treating cancer

If a driver is traveling to New York City, I-95 might be their route of choice. But they could also take I-78, I-87 or any number of alternate routes. Most cancers begin similarly, with many possible routes to the same disease. A new study found evidence that assessing the route to cancer on a case-by-case basis might make more sense than basing a patient's cancer treatment on commonly disrupted genes and pathways.

26 Feb 2014

Self Regional Healthcare, Clemson University expand partnership to accelerate rate of innovation in genetic medicine

A new partnership will establish formal collaboration among genetic researchers and Clemson University faculty at the Greenwood Genetic Center and Self Regional Healthcare, expanding an already successful working relationship.

24 Feb 2014

Boston Heart receives $1.0M in additional tax incentives through Life Sciences Tax Incentive Program

Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics with personal nutrition and lifestyle programs for patients with or at risk for heart disease, has received $1.0 million in additional tax incentives through the Life Sciences Tax Incentive Program.

21 Feb 2014

Ignyta reports preliminary results from ongoing Phase 1 clinical trial of RXDX-101

Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

21 Feb 2014

AlloMap test can be used to assess risk of dysfunction or rejection of a transplanted heart

A new UCLA-led study shows that a blood test commonly used to determine whether heart transplant recipients are rejecting their new organ can also predict potential rejection-related problems in the future.

19 Feb 2014

Precision Medicine News and Research

Merck Millipore announces joint development agreement with Sysmex Corporation

Researchers create statistical model to predict whether heart scans are useful in prescribing statins

Parasites in human are most likely to interact via food source

Three innovative tools to detect, test and initiate personalized drug treatment for seizures

Innovative study uses pharmacogenomic test to treat patients with psychotic disorders

Exosome Diagnostics closes Series B financing round with the raising of $27 million

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

Boston Heart Diagnostics announces commercial launch of FDA-cleared MPO test

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

Advanced Accelerator Applications agrees to acquire 100% shares of Imaging Equipment

Oxford Gene Technology announces acquisition of Cytocell

New tool may hold key to personalized medicine applications in the future

New research uncovers abnormal molecular signaling pathways for kidney failure

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

Study highlights the importance of personalized medicine for treating cancer

Self Regional Healthcare, Clemson University expand partnership to accelerate rate of innovation in genetic medicine

Boston Heart receives $1.0M in additional tax incentives through Life Sciences Tax Incentive Program

Ignyta reports preliminary results from ongoing Phase 1 clinical trial of RXDX-101

AlloMap test can be used to assess risk of dysfunction or rejection of a transplanted heart

Event guide: The 4th Precision Medicine in Inflammatory Bowel Disease Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News